LRRC superfamily expression in stromal cells predicts the clinical prognosis and platinum resistance of ovarian cancer

Table 3 Clinical data

Characteristic	Low expression of LRRC15	High expression of LRRC15	p	Statistic	Method
n	189	190
FIGO stage, n (%)			0.008		Fisher.test
Stage I	0 (0%)	1 (0.3%)
Stage II	18 (4.8%)	5 (1.3%)
Stage III	147 (39.1%)	148 (39.4%)
Stage IV	23 (6.1%)	34 (9%)
Primary therapy outcome, n (%)			0.028	9.08	Chisq.test
PD	10 (3.2%)	17 (5.5%)
SD	12 (3.9%)	10 (3.2%)
PR	14 (4.5%)	29 (9.4%)
CR	118 (38.3%)	98 (31.8%)
Race, n (%)			0.732	0.62	Chisq.test
Asian	7 (1.9%)	5 (1.4%)
Black or African American	14 (3.8%)	11 (3%)
White	164 (44.9%)	164 (44.9%)
Age, n (%)			0.963
< = 60	103 (27.2%)	105 (27.7%)
> 60	86 (22.7%)	85 (22.4%)
OS event, n (%)			0.967
Alive	74 (19.5%)	73 (19.3%)
Dead	115 (30.3%)	117 (30.9%)
Histologic grade, n (%)			0.430
G1	0 (0%)	1 (0.3%)
G2	20 (5.4%)	25 (6.8%)
G3	164 (44.4%)	158 (42.8%)
G4	1 (0.3%)	0 (0%)
Age, median (IQR)	59 (51, 69)	59 (51, 67)	0.744	18,304	Wilcoxon

FIGO stage and histologic grade did not meet the condition of a theoretical frequency > 5 or a total sample quantity > 40, so Fisher's exact test was used. Each level of the primary therapy outcome, race, and OS met the conditions of a theoretical frequency> 5 and a total sample quantity> 40, and the chi-square test was used. Age did not satisfy a normal distribution (P <0.05), and the Wilcoxon rank sum test was used.

ISSN: 1755-8794